Drug intelligence / Profile preview

cisplatin + nitroglycerin + vinorelbine

Development stage: Unknown
Lead developer: Michigan State University
Administration: Intravenous, Oral

Overview

The search results do not specifically mention a combination of cisplatin, nitroglycerin, and vinorelbine together as a single treatment regimen. While cisplatin and vinorelbine are well-documented as a chemotherapy combination for non-small cell lung cancer (NSCLC), there is no mention of nitroglycerin being used alongside these two drugs in the provided search results to form this specific three-drug combination.

Targets

sGC (Soluble Guanylyl Cyclase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on cisplatin + nitroglycerin + vinorelbine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + nitroglycerin + vinorelbine.

Explore the full profile